NCT04455594View on ClinicalTrials.gov

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

October 31, 2025

Conditions
Non-Small Cell Lung Cancer Stage IIIA
Interventions
DRUG

Almonertinib

Oral, 110mg QD

DRUG

Erlotinib

Oral, 150mg QD

DRUG

Cisplatin

Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles

DRUG

Carboplatin

Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles

DRUG

Pemetrexed

Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles

Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER